Literature DB >> 8336169

4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study.

H A van Diemen1, C H Polman, M M van Dongen, J J Nauta, R L Strijers, A C van Loenen, F W Bertelsmann, J C Koetsier.   

Abstract

This study reports on the neurophysiological measurements that were performed in the context of a randomized, double-blind, placebo-controlled, cross-over study with intravenously administered 4-aminopyridine (4-AP) in 70 patients with definite multiple sclerosis (MS). A beneficial effect of 4-AP was found for both visual evoked response and eye movement registration parameters. This study extends the experimental data obtained on animal nerve fibers, showing that 4-AP can improve impulse conduction in demyelinated nerve, to clinical data which indicate that 4-AP induces an objective improvement in the central nervous system function in MS-patients. It thereby also provides a theoretical basis for clinical efficacy of 4-AP in MS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8336169     DOI: 10.1016/0022-510x(93)90329-w

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  10 in total

Review 1.  Potassium channel blockers as an effective treatment to restore impulse conduction in injured axons.

Authors:  Riyi Shi; Wenjing Sun
Journal:  Neurosci Bull       Date:  2011-02       Impact factor: 5.203

Review 2.  [4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis].

Authors:  L Husseini; V I Leussink; B C Kieseier; H-P Hartung
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

Review 3.  Dalfampridine extended release: in multiple sclerosis.

Authors:  Claudine M Chwieduk; Gillian M Keating
Journal:  CNS Drugs       Date:  2010-10       Impact factor: 5.749

4.  Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.

Authors:  João Carlos Correia de Sa; Laura Airas; Emmanuel Bartholome; Nikolaos Grigoriadis; Heinrich Mattle; Celia Oreja-Guevara; Jonathan O'Riordan; Finn Sellebjerg; Bruno Stankoff; Karl Vass; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2011-05       Impact factor: 6.570

Review 5.  4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review.

Authors:  Henrik Boye Jensen; Mads Ravnborg; Ulrik Dalgas; Egon Stenager
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

Review 6.  Fampridine Prolonged Release: A Review in Multiple Sclerosis Patients with Walking Disability.

Authors:  Esther S Kim
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

7.  Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis.

Authors:  Keith C Hayes
Journal:  Neuropsychiatr Dis Treat       Date:  2011-04-28       Impact factor: 2.570

8.  Involvement of Kv1.3 and p38 MAPK signaling in HIV-1 glycoprotein 120-induced microglia neurotoxicity.

Authors:  J Liu; C Xu; L Chen; P Xu; H Xiong
Journal:  Cell Death Dis       Date:  2012-01-19       Impact factor: 8.469

Review 9.  A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS.

Authors:  Martin Hardmeier; Letizia Leocani; Peter Fuhr
Journal:  Mult Scler       Date:  2017-05-08       Impact factor: 6.312

10.  Dalfampridine effects on cognition, fatigue, and dexterity.

Authors:  Melanie Korsen; Rhina Kunz; Ulf Schminke; Uwe Runge; Thomas Kohlmann; Alexander Dressel
Journal:  Brain Behav       Date:  2016-11-11       Impact factor: 2.708

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.